- Home
- MLYS vs ATRO Comparison
MLYS vs ATRO Comparison
Compare MLYS & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- ATRO
- Stock Information
- Founded
- MLYS 2019
- ATRO 1968
- Country
- MLYS United States
- ATRO United States
- Employees
- MLYS N/A
- ATRO N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- MLYS Health Care
- ATRO Industrials
- Exchange
- MLYS Nasdaq
- ATRO Nasdaq
- Market Cap
- MLYS 1.0B
- ATRO 844.1M
- IPO Year
- MLYS 2023
- ATRO N/A
- Fundamental
- Price
- MLYS $14.30
- ATRO $32.53
- Analyst Decision
- MLYS Strong Buy
- ATRO Hold
- Analyst Count
- MLYS 4
- ATRO 1
- Target Price
- MLYS $27.00
- ATRO $32.00
- AVG Volume (30 Days)
- MLYS 871.8K
- ATRO 670.4K
- Earning Date
- MLYS 08-12-2025
- ATRO 07-31-2025
- Dividend Yield
- MLYS N/A
- ATRO N/A
- EPS Growth
- MLYS N/A
- ATRO N/A
- EPS
- MLYS N/A
- ATRO N/A
- Revenue
- MLYS N/A
- ATRO $816,288,000.00
- Revenue This Year
- MLYS N/A
- ATRO $8.33
- Revenue Next Year
- MLYS N/A
- ATRO $5.89
- P/E Ratio
- MLYS N/A
- ATRO N/A
- Revenue Growth
- MLYS N/A
- ATRO 13.73
- 52 Week Low
- MLYS $8.24
- ATRO $14.13
- 52 Week High
- MLYS $18.38
- ATRO $36.32
- Technical
- Relative Strength Index (RSI)
- MLYS 48.08
- ATRO 51.65
- Support Level
- MLYS $13.22
- ATRO $32.90
- Resistance Level
- MLYS $14.35
- ATRO $34.60
- Average True Range (ATR)
- MLYS 0.76
- ATRO 1.67
- MACD
- MLYS -0.04
- ATRO -0.41
- Stochastic Oscillator
- MLYS 51.92
- ATRO 30.46
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.